Pharma channel feed

Lil­ly qui­et­ly com­pletes pur­chase of Pad­cev com­peti­tor, es­ti­mat­ed at near­ly half a bil­lion dol­lars

Last year
Startups
Deals

Sens. Durbin and Grass­ley lever­age Medicare drug ne­go­ti­a­tion list to rein­vig­o­rate a push for drug prices in ads

Last year
Marketing

De­mo­c­rat law­mak­ers call on FDA to take steps to pre­vent mis­use of Or­ange Book

Last year
FDA+

FDA+ roundup: FDA is­sues fi­nal guid­ance on use of re­al-world ev­i­dence

Last year
R&D
FDA+

FDA re­ject­ed Out­look Ther­a­peu­tic­s' Lu­cen­tis ri­val, and the com­pa­ny's stock plunged

Last year
FDA+

Bris­tol My­ers se­cures FDA la­bel ex­pan­sion for ane­mia drug Re­blozyl

Last year
FDA+

Great Britain ap­proves sub­cu­ta­neous Tecen­triq weeks ahead of ex­pect­ed US de­ci­sion

Last year
FDA+

Pfiz­er chal­lenges Mod­er­na Covid vac­cine patents be­fore Patent Tri­al and Ap­peal Board

Last year
Law

Mar­ket­ingRx roundup: Ar­cutis joins crowd­ed pso­ri­a­sis ad mar­ket on TV; Mer­ck, GSK, Mod­er­na high­light im­mu­niza­tion month

Last year
Marketing

Medicare's first drug ne­go­ti­a­tion list like­ly to fu­el pub­lic pric­ing dis­cus­sions for phar­ma mar­keters

Last year
Marketing

Apel­lis trims staff, shrinks R&D plans to save mon­ey in face of loom­ing com­pe­ti­tion in oph­thal­mol­o­gy

Last year
People
R&D

Up­dat­ed: US se­lects first 10 drugs sub­ject to Medicare price ne­go­ti­a­tions

Last year
FDA+

Re­silience part­ners with Sau­di-based Lif­era to build bio­man­u­fac­tur­ing site

Last year
Deals
Manufacturing

FDA to hold off on en­forc­ing some parts of ma­jor sup­ply chain law un­til 2024

Last year
FDA+

Al­ny­lam plans to ap­peal Covid-19 vac­cine patent rul­ing in case against Mod­er­na

Last year
Law

ABPI, re­searchers crit­i­cize NHS’ In­no­v­a­tive Med­i­cines Fund, with no new ther­a­pies avail­able over a year af­ter for­ma­tion

Last year

Mod­er­na high­lights ten­nis leg­end Arthur Ashe in sec­ond ‘Change Mak­ers’ cam­paign at US Open, ahead of fall vac­cine sea­son

Last year
Marketing

FTC paus­es chal­lenge of Am­gen's $28B Hori­zon takeover to con­sid­er set­tle­ment

Last year
Law

Sanofi flies new flag for menin­gi­tis aware­ness, mark­ing one year to the Paris Par­a­lympics with three Team Sanofi ath­letes

Last year
Marketing

Phar­ma en­ters ‘age of un­cer­tain­ty’ amid chal­lenges from IRA, FTC and patent cliffs

Last year

FDA pub­lish­es On­copep­tides’ with­draw­al ap­peal for Swedish biotech’s can­cer drug Pepax­to

Last year
FDA+

Am­gen rais­es ‘bad’ cho­les­terol con­cerns in cam­paign with Amer­i­can Heart As­so­ci­a­tion

Last year
Marketing

HHS, vac­cine mak­ers prep for first-ever three-vac­cine avail­abil­i­ty with Covid, flu and RSV ahead of peak vi­ral sea­son

Last year
Marketing

As­traZeneca dis­putes IRA’s or­phan drug pro­vi­sions in lat­est le­gal chal­lenge to the law

Last year
FDA+
Law
First page Previous page 105106107108109110111 Next page Last page
A service from the Financial Times